SweetValueLab
Write for us

Pfizer Inc. — Intrinsic Value & Fair Price

PFE
NYSEHealthcareDrug Manufacturers - GeneralCIK 0000078003pfizer.comAbout PFE
Last close · Oct 16, 202629.58+0.14 (+0.48%)
Market cap$168.6B
Model value · DCF · Perpetuity growth · 5y
30.39
Pfizer closed at $29.58 — undervalued by 3% vs model.
12.41the model's range64.63

DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.

Other models
18.31 – 56.79
Wall St. target
30.50 3% below
Below model, 1y
10 of 21 days

Price and model value

Embed this card

PFE's close against its model value, as a 420×168 card for your own page. It updates nightly with this site and links back here.

Free to embed; keep the attribution link.
Loading chart…
What the marks mean
Daily close

Dividends

Quarterly · as of Oct 16, 2026
Yield, trailing 12 months
5.81%
#13 · Highest dividend yield
Past 2 years
low 5.53%high 7.83%
Dividends per share, a year at a time
$1.55Jul ’21$1.59Jul ’22$1.63Jul ’23$1.67Jul ’24$1.71Jul ’25$1.72TTM
Coverage
—
Raised
16 years in a row
Growth, 5 yrs
2.1% a year
Last change
+2.4% · Jan 2025
Every payment, with ex-dates · latest $0.43, paid Sep 1, 2026

Research on PFE

No posts on PFE yet.
Studied PFE from its filings? Guest posts are reviewed before they go live.Write about PFE →

How it is valued

Valued asMature & stable
Moderate growth (~11% recent)Moderate margins (12% net margin)Highly cyclical earningsStrong FCF yield (5.4%)
What growth the price implies: the reverse DCF

Key figures

FY2025 · chosen for mature companies
P/E
21.7×
EV / EBITDA
15.4×
FCF yield
5.4%
Dividend yield, TTM
5.81%
Beta
0.28
Cost of capital (WACC)
6.33%
Full financials

Analyst actions

third-party, quoted
10-08Cantor Fitzgerald · target28.00
10-06Scotiabank · target33.00
09-10HSBC · target30.00
07-06HSBC · “Hold” from “Buy”downgrade
Ratings, targets and estimates

Comparable companies

by business, not by industry label
2 more companies list PFE as a comparable
Side by side:vs BMYvs MRKvs JNJ

The weekly

One email a week across every stock we cover: 13F filings, insider trades, earnings and new research. It covers the whole market, not just PFE. No account.

About Pfizer

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

CEO
Albert Bourla
Headquarters
New York City, NY
Employees
75,000
IPO
1972-06-01
Full company profile

Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; the formulas are in how we value a stock.